hrp0098p2-285 | Thyroid | ESPE2024

Levothyroxine poisoning in children is usually benign: A multi-center experience from Turkey

Şen Küçük Kübra , Demir Şule , Deveci Sevim Reyhan , Akgül Fatma , Yalçın Gülşen , Eser Öznur , Bal Alkan , Ergün Elif , Öztürk Sercan , Anık Ahmet

Objective: The objective of this study was to investigate the clinical presentations, laboratory findings, treatment modalities, follow-up strategies employed for children with levothyroxine (LT4) poisoning.Materials-Methods: The study encompassed patients admitted to the respective centers between 2010-2023, who fulfilled the predefined study criteria. Findings were presented as percentages (%), median values with inter...

hrp0082wg5.2 | Paediatric and adolescent gynaecology | ESPE2014

Amenorrhea and Hypothalamic–Pituitary Dysfunction

Pitteloud N

Female reproductive disorders due to a hypothalamic–pituitary defect include hypothalamic amenorrhea (HA), polycystic ovarian syndrome (PCOS) and hyperprolactinemia. This talk will review the clinical presentation of HA, PCOS and hyperprolactinemia in adolescents and young adults and will provide an overview of recent clinical advances in the field....

hrp0097p1-506 | Growth and Syndromes | ESPE2023

Characteristics, effectiveness and safety data for patients with growth failure treated with recombinant IGF-1 and achieving adult or near-adult height: results from the Increlex® Global Registry

Bang Peter , Ramón Krauel Marta , Maghnie Mohamad , Woelfle Joachim , Sert Caroline , Perrot Valérie , Pennestri Daniele , Polak Michel

Background: severe primary insulin-like growth factor-1 deficiency (SPIGFD) is a rare growth disorder. Recombinant human insulin-like growth factor (IGF-1) (rhIGF-1; Increlex® [mecasermin]) replacement therapy is EU and US-approved for treating growth failure due to SPIGFD. The long-term therapeutic objective of rhIGF-1 treatment in SPIGFD is to improve adult height (AH). Objective: to describe the characteristics, safety and effectiveness data ...

hrp0097p1-199 | Thyroid | ESPE2023

Investigating the Incidence of Mild Neonatal Hyperthyrotropinaemia, a Multicentre Study

Howard-James N , McGlacken-Byrne SM , Kernan R , Carolan EC , Murphy NP

Background: Mild isolated neonatal hyperthyrotropinaemia (HTT), defined as elevated thyroid stimulating hormone (TSH) with normal free thyroxine (FT4) concentrations, may be identified by newborn screening programmes for congenital hypothyroidism (CHT) or when neonatal thyroid function tests (TFTs) are performed for a clinical indication. Reported HTT incidence rates vary (from 0.001-0.1%)1. Case definition also varies, with some authors using a TSH...

hrp0095p1-454 | Diabetes and Insulin | ESPE2022

Clinical and genetic evaluation of patients with maturity onset diabetes of the young (MODY) : Single center experience

Hande Turan , Bayramoglu Elvan , Gunes Kaya Didem , tarcin Gürkan , Bingöl Aydın Dilek , Ercan Oya , Evliyaoglu Olcay

Purpose: MODY is a monogenic diabetes with autosomal dominant inheritance that usually occurs in adolescence or young adulthood. It constitutes 1% of diabetes cases in childhood. The diagnosis of MODY is very difficult due to genetic heterogeneity, rarity, and clinical overlap with other diabetes types. In recent years, the diagnosis of MODY has become easier with genetic developments. On the other hand, misinterpretation of results can cause confusion. In thi...

hrp0098p1-63 | Growth and Syndromes 1 | ESPE2024

Long-term effectiveness and safety data from the Global Increlex® Registry in patients treated with rhIGF-1: Subgroup analysis of naïve pre-pubertal patients and patients with Laron syndrome

Ramón Krauel Marta , Woelfe Joachim , Polak Michel , Maghnie Mohamad , Beń-Skowronek Iwona , Sert Caroline , Perrot Valérie , Bang Peter

Background: The Global Increlex® Registry (NCT00903110) monitors real-world safety and effectiveness of recombinant human insulin-like growth factor (rhIGF-1; Increlex® [mecasermin]) in severe primary IGF-1 deficiency (SPIGFD). Patient characteristics, effectiveness and safety data from 2008–2023 are described.Methods: Descriptive analyses of registry data from children/adolescents age...

hrp0097p2-75 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Foetal exposures to endocrine-disrupting chemicals. INMA-ASTURIAS COHORT. SPAIN.

Cristina Rodríguez-Dehli Ana , Fernández-Somoano Ana , Riaño Galán Isolina , Tardon Adonina

Background: Endocrine-disrupting chemicals (EDCs) are serious and urgent threats to public health, due to the potentially serious adverse effects of EDCs on endocrine processes during susceptible periods of human development.Objective: To evaluate the levels endocrine disruptors at gestation.Material and methods: A pilot study. Data were obtained from 30 pregnant mothers recruited ...

hrp0084p1-146 | Miscelleaneous | ESPE2015

Salt Sensitivity of Blood Pressure at Age 7–8 Years in Preterm Born Children

Ruys Charlotte A , Lafeber Harrie N , Rotteveel Joost , Finken Martijn J J

Background: Preterm birth is associated with hypertension and increased fat contents in later life. Salt sensitivity (SS) could be a mechanism underlying this relationship. In adults SS has been recognised as a cause of hypertension that is related to low birth weight and obesity.Objective and hypotheses: We studied the prevalence of SS in 7–8-year old children born <32 weeks of gestation and/or with a birth weight <1500 g as well as its rel...

hrp0097p1-124 | Growth and Syndromes | ESPE2023

Caloric intake of 6 months-12 years old children with Prader Willi Syndrome under growth hormone treatment at a reference center.

Corripio Raquel , Couto Yolanda , Sánchez-Garvín Dunia , Pérez-Sánchez Jacobo , Garcia-Tirado Diana

Introduction: Prader-Willi Syndrome (PWS) is the most frequent cause of genetic obesity. It has been described that these patients require a reduction in caloric intake of 20- 40% compared to general population. Since 2000, with the approval of growth hormone (GH), the evolution of obesity has changed and it seems that caloric requirements could be different.Methodology: Observational, descriptive, cross-sectional and re...

hrp0086rfc4.4 | Pathophysiology of Obesity | ESPE2016

Metabolic Syndrome Markers Correlate with Gut Microbiome Activity in Children Born Very Preterm

Chiavaroli Valentina , Jayasinghe Thilini N , Ekblad Cameron , Derraik Jose , Hofman Paul , O'Sullivan Justin , Cutfield Wayne

Background: Fifteen years ago children born very preterm (<32 weeks of gestation) were reported to be insulin resistant. Neonatal intensive care has since improved considerably, but it is unclear whether this has affected long-term outcomes in those born preterm. Abnormalities in gut microbiome, which influence host metabolism, have been found in preterm newborns.Objective and hypotheses: We aimed to assess whether children born very preterm still ha...